Direxion Daily MSFT Bull 1.5X Shares

GraniteShares 2x Long MSFT Daily ETF

GraniteShares 1.5x Long META Daily ETF

GraniteShares 1.5x Long NVDA Daily ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

VS TR 2x Long VIX Futures ETF

ProShares UltraPro QQQ

Direxion Daily S&P Biotech Bull 3X ETF

T-REX 2X Inverse Tesla Daily Target ETF

ProShares Ultra VIX Short-Term Futures

GraniteShares 1.5x Short NVDA Daily ETF

Direxion Daily TSLA Bull 1.5X Shares

Direxion Dly S&P Oil&Gs Ex&Prd Bl 3X ETF

Guggenheim Solar ETF

ProShares UltraPro Short QQQ

Direxion Daily S&P Biotech Bear 3X ETF

Volatility Shares Trust 2x Ether ETF

United States Oil Fund

GraniteShares 1.5x Long Coinbase Daily ETF

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

Regulus Therapeutics Inc. Common Stock

Jeffs' Brands Ltd Ordinary Shares

WW International Inc. Common Stock

Petros Pharmaceuticals Inc. Common Stock

LogicMark Inc. Common Stock

Sharps Technology Inc. Common Stock

Nvni Group Limited Ordinary Shares

New Gold Inc.

Urgent.ly Inc. Common Stock

Qorvo Inc. Common Stock

AgEagle Aerial Systems Inc. Common Stock

Autonomix Medical Inc. Common Stock

Snap Inc. Class A Common Stock

Super Micro Computer Inc. Common Stock

MicroAlgo Inc. Ordinary Shares

AtriCure Inc. Common Stock

Hillenbrand Inc Common Stock

CoStar Group Inc. Common Stock

Wearable Devices Ltd. Ordinary Share

First Solar Inc. Common Stock

Click here to get full coverage on Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last? - Yahoo

Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last?  Yahoo

Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last? - Yahoo

Click here to get full coverage on Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last? - Nasdaq

Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last?  Nasdaq

Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last? - Nasdaq

Click here to get full coverage on UroGen's Bladder Cancer Drug Achieves 60% Long-Term Success Rate in Phase 1 Trial: Key Data Released - Stock Titan

UroGen's Bladder Cancer Drug Achieves 60% Long-Term Success Rate in Phase 1 Trial: Key Data Released  Stock Titan

UroGen's Bladder Cancer Drug Achieves 60% Long-Term Success Rate in Phase 1 Trial: Key Data Released - Stock Titan

Click here to get full coverage on UroGen Pharma (URGN) Reports Positive Safety Outcomes in Cancer Study | URGN Stock News - GuruFocus

UroGen Pharma (URGN) Reports Positive Safety Outcomes in Cancer Study | URGN Stock News  GuruFocus

UroGen Pharma (URGN) Reports Positive Safety Outcomes in Cancer Study | URGN Stock News - GuruFocus

Click here to get full coverage on UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates - Benzinga

UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates  Benzinga

UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates - Benzinga

Click here to get full coverage on $URGN stock is up 7% today. Here's what we see in our data. - Nasdaq

$URGN stock is up 7% today. Here's what we see in our data.  Nasdaq

$URGN stock is up 7% today. Here's what we see in our data. - Nasdaq

Click here to get full coverage on New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC - Stock Titan

New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC  Stock Titan

New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC - Stock Titan

Click here to get full coverage on UroGen Pharma (URGN) Reports Nearly Four-Year Response Duration for JELMYTO | URGN Stock News - GuruFocus

UroGen Pharma (URGN) Reports Nearly Four-Year Response Duration for JELMYTO | URGN Stock News  GuruFocus

UroGen Pharma (URGN) Reports Nearly Four-Year Response Duration for JELMYTO | URGN Stock News - GuruFocus

Click here to get full coverage on UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance

UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ...  Yahoo Finance

UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance

Click here to get full coverage on Breakthrough Cancer Treatment JELMYTO Maintains 47.8-Month Response in Upper Tract Cancer Patients - Stock Titan

Breakthrough Cancer Treatment JELMYTO Maintains 47.8-Month Response in Upper Tract Cancer Patients  Stock Titan

Breakthrough Cancer Treatment JELMYTO Maintains 47.8-Month Response in Upper Tract Cancer Patients - Stock Titan

Click here to get full coverage on UroGen Pharma (URGN) Updates Promising Results from UGN-102 Tria - GuruFocus

UroGen Pharma (URGN) Updates Promising Results from UGN-102 Tria  GuruFocus

UroGen Pharma (URGN) Updates Promising Results from UGN-102 Tria - GuruFocus

Click here to get full coverage on Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now? - Yahoo Finance

Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now?  Yahoo Finance

Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now? - Yahoo Finance

Click here to get full coverage on New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC - Stock Titan

New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC  Stock Titan

New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC - Stock Titan

Click here to get full coverage on UroGen Pharma (URGN) Reports Promising Long-Term Results for Bla - GuruFocus

UroGen Pharma (URGN) Reports Promising Long-Term Results for Bla  GuruFocus

UroGen Pharma (URGN) Reports Promising Long-Term Results for Bla - GuruFocus

Click here to get full coverage on Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates  Yahoo Finance

Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on URGN: UroGen Pharma's UGN-102 Demonstrates Promising Results in Bladder Cancer Treatment | URGN Stock News - GuruFocus

URGN: UroGen Pharma's UGN-102 Demonstrates Promising Results in Bladder Cancer Treatment | URGN Stock News  GuruFocus

URGN: UroGen Pharma's UGN-102 Demonstrates Promising Results in Bladder Cancer Treatment | URGN Stock News - GuruFocus

Click here to get full coverage on Phase 3 Trial: New Bladder Cancer Drug Shows 81% Success at 18 Months | URGN Stock News - Stock Titan

Phase 3 Trial: New Bladder Cancer Drug Shows 81% Success at 18 Months | URGN Stock News  Stock Titan

Phase 3 Trial: New Bladder Cancer Drug Shows 81% Success at 18 Months | URGN Stock News - Stock Titan

Click here to get full coverage on Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - Yahoo Finance

Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN)  Yahoo Finance

Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - Yahoo Finance

Click here to get full coverage on Major Breakthrough: UroGen to Reveal 18-Month Cancer Treatment Data at Leading Urology Conference - Stock Titan

Major Breakthrough: UroGen to Reveal 18-Month Cancer Treatment Data at Leading Urology Conference  Stock Titan

Major Breakthrough: UroGen to Reveal 18-Month Cancer Treatment Data at Leading Urology Conference - Stock Titan

Click here to get full coverage on UroGen Revenue Hits $90.4M, UGN-102 Trial Shows 80% Success Rate - Stock Titan

UroGen Revenue Hits $90.4M, UGN-102 Trial Shows 80% Success Rate  Stock Titan

UroGen Revenue Hits $90.4M, UGN-102 Trial Shows 80% Success Rate - Stock Titan

Click here to get full coverage on UroGen: Upcoming PDUFA, Some Concerns Remain (NASDAQ:URGN) - Seeking Alpha

UroGen: Upcoming PDUFA, Some Concerns Remain (NASDAQ:URGN)  Seeking Alpha

UroGen: Upcoming PDUFA, Some Concerns Remain (NASDAQ:URGN) - Seeking Alpha

Click here to get full coverage on UroGen's Major Pipeline Play: Revolutionary Cancer-Fighting Virus Acquisition Reshapes Growth Strategy - Stock Titan

UroGen's Major Pipeline Play: Revolutionary Cancer-Fighting Virus Acquisition Reshapes Growth Strategy  Stock Titan

UroGen's Major Pipeline Play: Revolutionary Cancer-Fighting Virus Acquisition Reshapes Growth Strategy - Stock Titan

Click here to get full coverage on Improved Revenues Required Before UroGen Pharma Ltd. (NASDAQ:URGN) Shares Find Their Feet - simplywall.st

Improved Revenues Required Before UroGen Pharma Ltd. (NASDAQ:URGN) Shares Find Their Feet  simplywall.st

Improved Revenues Required Before UroGen Pharma Ltd. (NASDAQ:URGN) Shares Find Their Feet - simplywall.st

Click here to get full coverage on UroGen Pharma to Present at Upcoming Investor Conferences - Business Wire

UroGen Pharma to Present at Upcoming Investor Conferences  Business Wire

UroGen Pharma to Present at Upcoming Investor Conferences - Business Wire

Click here to get full coverage on UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102 - Business Wire

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102  Business Wire

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102 - Business Wire

Click here to get full coverage on UroGen Pharma Announces Encouraging Results from a Phase 1 Dose- - GuruFocus

UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-  GuruFocus

UroGen Pharma Announces Encouraging Results from a Phase 1 Dose- - GuruFocus

Click here to get full coverage on Scotiabank Initiates Coverage of UroGen Pharma (URGN) with Promi - GuruFocus

Scotiabank Initiates Coverage of UroGen Pharma (URGN) with Promi  GuruFocus

Scotiabank Initiates Coverage of UroGen Pharma (URGN) with Promi - GuruFocus

Click here to get full coverage on New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Dem - GuruFocus

New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Dem  GuruFocus

New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Dem - GuruFocus

Click here to get full coverage on Pre-Market Earnings Report for March 10, 2025 : FNV, BNTX, URGN, TLS, ALGS, DRIO - Nasdaq

Pre-Market Earnings Report for March 10, 2025 : FNV, BNTX, URGN, TLS, ALGS, DRIO  Nasdaq

Pre-Market Earnings Report for March 10, 2025 : FNV, BNTX, URGN, TLS, ALGS, DRIO - Nasdaq

Click here to get full coverage on UroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong Buy - Seeking Alpha

UroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong Buy  Seeking Alpha

UroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong Buy - Seeking Alpha

Click here to get full coverage on High Growth Tech Stocks In The US To Watch April 2025 - simplywall.st

High Growth Tech Stocks In The US To Watch April 2025  simplywall.st

High Growth Tech Stocks In The US To Watch April 2025 - simplywall.st

Click here to get full coverage on UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC - Business Wire

UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC  Business Wire

UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC - Business Wire

Click here to get full coverage on UroGen Pharma stock hits 52-week low at $9.02 - Investing.com

UroGen Pharma stock hits 52-week low at $9.02  Investing.com

UroGen Pharma stock hits 52-week low at $9.02 - Investing.com

Click here to get full coverage on (URGN) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

(URGN) Pivots Trading Plans and Risk Controls  news.stocktradersdaily.com

(URGN) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Click here to get full coverage on This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday  Benzinga

This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Click here to get full coverage on UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  Business Wire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Click here to get full coverage on OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Durat - GuruFocus

OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Durat  GuruFocus

OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Durat - GuruFocus

Click here to get full coverage on ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 - Business Wire

ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025  Business Wire

ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 - Business Wire

Click here to get full coverage on UroGen Announces FDA Acceptance of its New Drug Application for UGN-102 - Business Wire

UroGen Announces FDA Acceptance of its New Drug Application for UGN-102  Business Wire

UroGen Announces FDA Acceptance of its New Drug Application for UGN-102 - Business Wire

Click here to get full coverage on UroGen Announces Data Presentations at the American Urological A - GuruFocus

UroGen Announces Data Presentations at the American Urological A  GuruFocus

UroGen Announces Data Presentations at the American Urological A - GuruFocus

Click here to get full coverage on UroGen Announces Updated 18-Month Duration of Response (DOR) of - GuruFocus

UroGen Announces Updated 18-Month Duration of Response (DOR) of  GuruFocus

UroGen Announces Updated 18-Month Duration of Response (DOR) of - GuruFocus

Click here to get full coverage on New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) - Business Wire

New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)  Business Wire

New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) - Business Wire

Click here to get full coverage on New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO - Business Wire

New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO  Business Wire

New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO - Business Wire

Click here to get full coverage on UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025 - Business Wire

UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025  Business Wire

UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025 - Business Wire

Click here to get full coverage on 10 Best Small-Cap Growth Stocks to Buy Now - Insider Monkey

10 Best Small-Cap Growth Stocks to Buy Now  Insider Monkey

10 Best Small-Cap Growth Stocks to Buy Now - Insider Monkey

Click here to get full coverage on UroGen Pharma Reports Strong Pipeline Progress and Revenue Growth - TipRanks

UroGen Pharma Reports Strong Pipeline Progress and Revenue Growth  TipRanks

UroGen Pharma Reports Strong Pipeline Progress and Revenue Growth - TipRanks

Click here to get full coverage on UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025 - Business Wire

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025  Business Wire

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025 - Business Wire

Click here to get full coverage on UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024 - Business Wire

UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024  Business Wire

UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024 - Business Wire

Click here to get full coverage on UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants - Business Wire

UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants  Business Wire

UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants - Business Wire

Click here to get full coverage on UroGen Pharma Ltd. SEC 10-K Report - TradingView

UroGen Pharma Ltd. SEC 10-K Report  TradingView

UroGen Pharma Ltd. SEC 10-K Report - TradingView

Click here to get full coverage on UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC - Yahoo Finance

UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC  Yahoo Finance

UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC - Yahoo Finance

Click here to get full coverage on UroGen Pharma Posts Wider Loss In Q4 - Quick Facts - Nasdaq

UroGen Pharma Posts Wider Loss In Q4 - Quick Facts  Nasdaq

UroGen Pharma Posts Wider Loss In Q4 - Quick Facts - Nasdaq

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on Form 8-K - Current report - ADVFN

UroGen Pharma Ltd (URGN)

Price Chart

Key Statistics

Technicals

About URGN

Latest News

Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last? - Yahoo

Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last? - Nasdaq

UroGen's Bladder Cancer Drug Achieves 60% Long-Term Success Rate in Phase 1 Trial: Key Data Released - Stock Titan

Advanced Charts

Top Gainers

Top Losers